Moreover, NSCLC patients with a high TMB score, who received nivolumab (anti-PD-L1), had longer PFS and a higher objective response rate (ORR) than those who received chemotherapy [59]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.